Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Other OTC
  5. EpiCept Corp
  6. Company
       US2942643048

EPICEPT CORP

SummaryNewsCompany 
Business Summary
Immune Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of novel targeted therapeutic agents in the fields of immunology, inflammation, dermatology and oncology. It operates though acquiring, developing and commercializing prescription drug products. Its lead product is bertilimumab, which is a fully human, anti-eotaxin-1, a regulator of immuno-inflammation. The Company is developing NanoCyclo, which is a nano-encapsulated formulation of cyclosporine-A for the treatment of atopic dermatitis and psoriasis. The CompanyÔÇÖs oncology portfolio includes Ceplene, which a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
Managers
Name Title Age Since
Adeel Ahmed-Daudpota President & Chief Executive Officer 33 2021
Devin J. Shaw Chief Financial Officer 33 2021
John Zhang, Dr. Vice President-Research & Development - 2017
John A. Neczesny Independent Director 56 2016
Jeffrey Paley, Dr. Independent Director 52 2016
John P. Clark Secretary & Controller 48 2017
Members of the board
Name Title Age Since
David Sidransky, Dr. Director 59 2013
Daniel Kazado Director 55 2016
John A. Neczesny Independent Director 56 2016
Jeffrey Paley, Dr. Independent Director 52 2016
Anthony S. Fiorino, Dr. Director 52 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 172,878,093 172,878,093 100.0% 0 0.0% 100.0%
Stock B 0 3,713 0 0.0% 0 0.0%
Shareholders
NameEquities%
Heights Capital Management, Inc. 251,029 0.14%
Barclays Capital, Inc. 187,059 0.10%
Renaissance Technologies LLC 138,205 0.076%
The Vanguard Group, Inc. 136,841 0.075%
Edmond de Rothschild (Suisse) SA (Private Banking) 86,325 0.047%
Hudson Bay Capital Management LP 64,159 0.035%
Anson Funds Management LP 41,935 0.023%
Credit Suisse Securities (USA) LLC (Broker) 38,399 0.021%
Intellectus Partners LLC 31,082 0.017%
Goldman Sachs & Co. LLC (Private Banking) 28,405 0.016%
Company contact information
Immune Pharmaceuticals, Inc.
1 Bridge Plaza North
Suite 270
Englewood Cliffs, NJ 07024

Phone : +1.201.464.2677
Web : http://www.immunepharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of EpiCept Corp
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
EPICEPT CORP0
JOHNSON & JOHNSON5.32%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.17.22%244 227
ELI LILLY AND COMPANY47.15%225 231
MERCK & CO., INC.0.55%208 206
ABBVIE INC.2.18%193 488
ASTRAZENECA PLC22.92%192 243
NOVARTIS AG-6.91%189 275
BRISTOL-MYERS SQUIBB COMPANY-6.11%129 416
SANOFI8.83%124 649
AMGEN INC.-9.24%118 499
GLAXOSMITHKLINE PLC6.87%98 943
ALLERGAN PLC0.97%63 659
CHUGAI PHARMACEUTICAL CO., LTD.-21.86%61 190
BAYER AG1.32%55 574
JIANGSU HENGRUI MEDICINE CO., LTD.-47.18%49 318
DAIICHI SANKYO COMPANY, LIMITED-18.42%47 906
TAKEDA PHARMACEUTICAL COMPANY LIMITED-15.02%43 832
ASTELLAS PHARMA INC.23.43%31 917